Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.60 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.55 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549844 | 0.97 | NR4A2 (0.62) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL8835204 | 0.83 | NR4A2 (0.55) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL10509345 | 0.75 | CYP2D6 (0.54) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL10626077 | 0.74 | CYP2D6 (0.45) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL3398399 | 0.73 | NR4A2 (0.76) | NR4A2CYP2D6CYP2C19TAAR1TDP1 | |
| SCHEMBL9271568 | 0.73 | KMT5B (0.81) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL10891775 | 0.73 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1613404 | 0.73 | KMT5B (0.81) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL9540195 | 0.73 | KMT5B (0.81) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 | |
| SCHEMBL10509046 | 0.72 | CYP2D6 (0.55) | NR4A2KMT5BKMT5CSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-5596002-A | TREATMENT OF ANTIBIOTIC RESISTANT MICROORGANISMS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | NR4A2 2911/4885KMT5B 1183/4885KMT5C 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.